ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 847

Basic Calcium Phosphate Crystals Induce Osteoarthritis-Associated Changes in Chondrocyte Phenotype through Activation of Calcium/Calmodulin Kinase 2

Jing Rong1, Bregina Pool2, Mark Zhu3, Jacob Munro4, Geraldine M. McCarthy5, Jillian Cornish2, Nicola Dalbeth1 and Raewyn Poulsen3, 1University of Auckland, Auckland, New Zealand, 2Department of Medicine, University of Auckland, Auckland, New Zealand, 3Medicine, University of Auckland, Auckland, New Zealand, 4Orthopaedics, Auckland City Hospital, Auckland, New Zealand, 5Mater Misericordiae University Hospital, Dublin, Ireland

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: basic calcium phosphate, Cell Signaling, chondrocytes, crystal-induced arthritis and osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S085 ACR Abstract: Osteoarthritis & Joint Biology–Basic Science (846–850)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Basic calcium phosphate crystals (BCP) are frequently found in osteoarthritic joints. Whether BCP crystal deposition is a cause or consequence of osteoarthritis (OA) pathology remains contentious. In OA, chondrocytes undergo a phenotype shift resulting in increased production of cartilage degrading enzymes (particularly matrix metalloproteinase 13, MMP13) and production of abnormal extracellular matrix components (eg type X collagen, COL10), disrupting cartilage integrity and leading to cartilage loss. The purpose of this study was to determine whether BCP crystals can induce the OA-associated phenotype change in chondrocytes.

Methods:

Primary human chondrocytes were exposed to 50µg/ml BCP crystals (equivalent to the concentration present in synovial fluid in patients with OA) for up to 48h. Chondrocyte phenotypic marker expression (SOX9, RUNX2, IHH, MMP13, COL10A1) was measured by RT-qPCR, ELISA and immunocytochemistry. BCP crystal-induced signalling pathway activation was identified using western blotting, pharmacological inhibitors and RNA interference. Intracellular calcium levels were measured using the calcium-sensitive dye, Fluo4.

Results: Exposure to BCP crystals resulted in changes in chondrocyte phenotypic markers indicating cells were adopting a more OA-like phenotype. Expression of SOX9 was lower, and RUNX2, IHH and MMP13 higher, in BCP crystal-exposed cells compared to untreated controls. COL10 (a late-stage marker of the osteoarthritic chondrocyte phenotype) was detected at both the RNA and protein level in BCP crystal-exposed but not in untreated cells. BCP crystal exposure resulted in a rapid increase in intracellular calcium levels that was abolished by co-treatment with an antagonist preventing the release of calcium from intracellular stores. The BCP-induced increase in intracellular calcium was dependent on free Ca2+ in the extracellular environment and activity of the extracellular calcium sensing receptor (CaSR, a receptor for calcium first messenger signalling and activator of calcium release from intracellular stores). Exposure to BCP crystals resulted in activation of the calcium-sensitive enzyme, calcium/calmodulin kinase 2 (CaMK2) by a mechanism dependent on CaSR activity and the release of calcium from intracellular stores. Inhibition of CaMK2 activity or knockdown of either of the CaMK2 isoforms expressed by human chondrocytes (δ and γ) mitigated the ability of BCP crystals to induce OA-associated changes in chondrocyte phenotype.

Conclusion: BCP crystal exposure results in OA-like changes in chondrocyte phenotype by CaSR-mediated activation of CaMK2. Increased CaMK2 activity has been observed in osteoarthritis and is implicated in the disease-associated change in chondrocyte phenotype. Our data indicate the presence of BCP crystals within osteoarthritic joints may contribute to the increased CaMK2 activation seen in disease and may promote OA progression by inducing disease-associated changes in chondrocyte phenotype.


Disclosure: J. Rong, None; B. Pool, None; M. Zhu, None; J. Munro, None; G. M. McCarthy, None; J. Cornish, None; N. Dalbeth, Horizon, 5,Kowa, 5,Amgen Inc., 2,AstraZeneca/Ironwood, 2,AbbVie Inc., 8,Pfizer, Inc., 8,Janssen, 8; R. Poulsen, Research grants from the Health Reserach Council of NZ and Arthritis, NZ, 2.

To cite this abstract in AMA style:

Rong J, Pool B, Zhu M, Munro J, McCarthy GM, Cornish J, Dalbeth N, Poulsen R. Basic Calcium Phosphate Crystals Induce Osteoarthritis-Associated Changes in Chondrocyte Phenotype through Activation of Calcium/Calmodulin Kinase 2 [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/basic-calcium-phosphate-crystals-induce-osteoarthritis-associated-changes-in-chondrocyte-phenotype-through-activation-of-calcium-calmodulin-kinase-2/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/basic-calcium-phosphate-crystals-induce-osteoarthritis-associated-changes-in-chondrocyte-phenotype-through-activation-of-calcium-calmodulin-kinase-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology